Martin K. Safo, Ph.D.
Director, Structural Biology Shared Resource
Research program member: Developmental Therapeutics
800 E. Leigh St.
Richmond, VA 23298
Professor, Medicinal Chemistry, School of Pharmacy
PhD, University of Notre Dame (1991)
Hepatocellular carcinoma (HCC) is the fifth most common and the third most lethal cancer worldwide. Currently, surgery is the most effective treatment with curative potential, but it is associated with a mediocre 5-year survival rate of 60%. Pyruvate kinase is responsible for the final rate-limiting step of glycolysis and ATP production required for supplying energy critical for cancer cell survival. Downregulation of the pyruvate kinase isoform PKLR is known to suppress cancer progression of HCC and thus represents a novel route to a highly targeted, anticancer, therapeutic drug. Our group is targeting the inhibition of PKLR as a means to control cell proliferation and tumor growth of liver cancer. Our long-term objective is to introduce a novel class of anticancer drugs with minimal side effects.
Animal models,Apoptosis,Drug discovery